January brings a start to 2008, and allows us to briefly reflect where we are coming from, and where we are heading in the new year.
and Margaret O'Connor, PhD, suggest that for most patients, MCI represents a transitional state between normal ageing and mild dementia, with multiple subtypes and involvement of symptoms of other cognitive domains, such as executive function, language, and visuospatial dysfunction. As we move closer to disease-modifying therapy for Alzheimer's disease, early identification is becoming even more critical for identifying patients who have an opportunity to benefit from treatment.
Ronald C. Petersen, MD, PhD, and Selamawit Negash, PhD, present an algorithm to assist clinicians in subclassifying various types of MCI, and discusses specific progression factors including genetic, neuroimaging, biomarker, and clinical characteristics.
Charles L. Bowden, MD, and colleagues assess the tolerability of and efficacy with lamotrigine (LTG) administered concomitantly with commonly prescribed bipolar medications. The percentages of patients with any reported adverse event and reported adverse events of mood symptoms or rash were comparable between those taking LTG with or without other concomitant bipolar medications. Adverse events in >10% of patients in at least one subgroup were headache, infection, nausea, rash, influenza, diarrhea, dizziness, and somnolence. Baseline scores on psychiatric rating scales improved similarly with LTG co-administered with other bipolar medications, and the pattern of results did not differ by baseline polarity of mood symptoms. Therefore, LTG co-administered with valproate, lithium, an atypical antipsychotic, or a selective serotonin reuptake inhibitor in the treatment of bipolar disorder seemed to be well tolerated and was associated with clinical improvement.
In addition, two communiques address pica and novel neuropeptides. Alan Jay Lerner, MD, describes the case of a woman with autism.
severe mental retardation, and seizures, who had severe and persistent pica associated with features of frontal disinhibition. In this case, the pica was markedly reduced with the atypical antipsychotic agent olanzapine. Chi-Un Pae, MD, discusses some preliminary thoughts about a novel neuropeptide "Semax" that increases brain-derived neurotrophic factor and, as such, could potentially have effects of hippocampal neuroplasticity and perhaps mood and attention. Of course, controlled studies would be needed to determine whether these hypothesized effects indeed are influenced by this neuropeptide.
Finally, I would like to thank the excellent and hard work of our peer reviewers, without whom we could not maintain the high standards of the journal. I would also like to thank our excellent colum- 
